Comparative Pharmacology
Head-to-head clinical analysis: MEPRO ASPIRIN versus NAPROSYN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MEPRO ASPIRIN versus NAPROSYN.
MEPRO-ASPIRIN vs NAPROSYN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Meprobamate enhances GABAergic inhibition by binding to GABA-A receptors, increasing chloride conductance, while aspirin inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. This results in decreased inflammation, pain, and fever.
Oral: 1-2 tablets (each containing 200 mg meprobamate and 325 mg aspirin) every 6 hours as needed; maximum 6 tablets per day.
250-500 mg orally twice daily; maximum 1500 mg/day. For extended-release: 750-1000 mg orally once daily.
None Documented
None Documented
Aspirin: 15–20 minutes (rapid hydrolysis to salicylic acid). Salicylic acid: 2–3 hours at low doses (300–600 mg), 15–30 hours at high anti-inflammatory doses (1–2 g) due to saturable metabolism. Clinically, dosing interval is adjusted based on salicylate half-life.
Terminal elimination half-life is 12-17 hours. This long half-life allows twice-daily dosing, but may lead to drug accumulation in elderly or renally impaired patients.
Renal (primarily as salicyluric acid, salicyl glucuronides, and free salicylic acid). At therapeutic doses, about 10% is excreted as free salicylic acid; at toxic doses, this increases to >50%. Biliary/fecal elimination is minimal (<5%).
Renal excretion of conjugated metabolites accounts for approximately 95% of a dose, with 1-2% as unchanged naproxen. Fecal excretion is minimal (<5%).
Category D/X
Category C
NSAID / Antiplatelet
NSAID